Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | NEK2 | P51955 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173410 | 1.00 | AXL (0.73) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL21437508 | 0.91 | AXL (0.74) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL25299781 | 0.87 | PTK2 (0.65) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL30590501 | 0.87 | AXL (0.69) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL25838809 | 0.87 | AXL (0.69) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL21437921 | 0.86 | AXL (0.70) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL21446913 | 0.85 | AXL (0.87) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL29394359 | 0.85 | AXL (1.00) | AXLAURKAAURKBNEK2ALK | |
| Dubermatinib SCHEMBL12813478 | 0.85 | AXL (1.00) | AXLAURKAAURKBNEK2ALK | |
| SCHEMBL24727537 | 0.84 | AXL (0.86) | AXLAURKAAURKBNEK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220380348-A1 | AXL INHIBITOR FORMULATIONS | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11400091-B2 | AXL kinase inhibitors and use of the same | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021067772-A1 | AXL INHIBITOR FORMULATIONS | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067772-A1 | AXL INHIBITOR FORMULATIONS | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3773591-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10888562-B1 | — | — | 2021-01-12 | — | — | US | disclosed |
| US-10888562-B1 | — | — | 2021-01-12 | — | — | US | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400091-B2 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | AXL 1/4885AURKA 100/4885AURKB 167/4885 |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | AXL 1/4885AURKA 100/4885AURKB 167/4885 |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885AURKA 81/4885AURKB 146/4885 |
| US-20220380348-A1 | AXL INHIBITOR FORMULATIONS | AXL, FYN, SYK | AXL 1/4885AURKA 742/4885AURKB 1005/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885AURKA 94/4885AURKB 164/4885 |
| US-10888562-B1 | — | TP53, TARBP2, FLT3 | AXL 927/4885AURKA 590/4885AURKB 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.